Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against the other biotech stocks. Biotechnology stocks are among the most volatile in the ...

Shares of Madrigal (MDGL) have gained 34.6% over the past four weeks to close the last trading session at $288.58, but there could still be a solid upside left in the stock if short-term price ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...

If Altimmune can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Click ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a ...

Below is Validea's guru fundamental report for MADRIGAL PHARMACEUTICALS INC (MDGL). Of the 22 guru strategies we follow, MDGL rates highest using our Contrarian Investor model based on the ...

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ:MDGL), could bode well for Novo Nordisk A/S (NYSE:NVO). The pharma ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.